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BACKGROUND: Because anaplastic thyroid cancer is a rare malignancy with a high mortality rate, the benefit of multimodality treat-
ment was evaluated. METHODS: Overall survival was determined in the 2742 patients captured by the National Cancer Database who
were diagnosed with anaplastic thyroid cancer between 1998 and 2008. Kaplan-Meier analysis and then Cox proportional hazard
regression was performed, controlling for patient characteristics and treatment. RESULTS: Only older age (adjusted hazard ratio
[AHR] for85 years53.43, 95% confidence interval [CI]52.34-5.03; for 75-84 years, AHR52.85, 95% CI5 1.97-4.11; for 65-74 years,
AHR52.20, 95% CI5 1.53-3.15; for 45-64 years, AHR52.08, 95% CI5 1.47-2.95) and omission of treatment were associated with
greater mortality (omission of surgery: AHR5 1.79, 95% CI5 1.61-1.99; omission of radiation therapy: AHR5 1.56; 95% CI5 1.41-1.73; and
omission of chemotherapy: AHR5 1.28, 95% CI5 1.15-1.43). In subgroup analysis of patients with American Joint Committee on Cancer
stage IVA, IVB, and IVC anaplastic thyroid cancer, combination therapy with surgery, radiation, and chemotherapy was associated a
difference in median survival of months. CONCLUSIONS: Multimodality management of anaplastic thyroid cancer results in a marginal
treatment benefit. The poor overall survival of all anaplastic thyroid cancer patients, regardless of treatment, emphasizes the need for
informed patients whose preferences are incorporated into treatment decision-making. Cancer 2013;119:3133-9. VC 2013 American Can-
cer Society.
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INTRODUCTION
Anaplastic thyroid cancer is a rare but deadly form of thyroid cancer. Even though it accounts for only 1% to 2% of the
thyroid cancer cases each year, the relative 5-year survival of patients diagnosed with this cancer is a mere 7%.1 Anaplastic
thyroid cancer is more common in the elderly, and it almost always arises after preexisting well-differentiated thyroid
cancer.2,3
Because anaplastic thyroid cancer is rare, there are very few studies with a cohort of patients large enough to
adequately assess the effect of treatment on outcome. Several single-institution studies with small sample sizes (N5 25 to
N5 134), have conflicting results.4-6 There are international and Surveillance, Epidemiology, and End Results (SEER)
studies,2,7,8 but even with these studies, the largest cohort includes only 516 patients.2 Recent clinical guidelines advocate
combination therapy for stage IVA and IVB patients who want aggressive management,9 but the benefit of this multimo-
dality treatment is still unknown.
We used the National Cancer Database (NCDB), which includes 70% of all cancers in the United States,10 to evalu-
ate overall survival in the 2742 patients diagnosed with anaplastic thyroid cancer between 1998 and 2008. We hypothe-
sized that there would be a statistically significant difference in survival with more intensive treatment but that the median
difference in survival by months would be small and possibly clinically insignificant.
MATERIALS AND METHODS
Data Source and Study Population
The NCDB is a national cancer registry that is a joint project of the American College of Surgeons Commission on Cancer
and the American Cancer Society. The NCDB captures 70% of all cancers in the United States, and all data are coded and
reported according to nationally established protocols.10 Data came from the NCDB Participant User File (PUF). Data
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from thyroid cancer cases were queried and International
Classification of Diseases for Oncology (ICD-O) codes
consistent with anaplastic thyroid cancer were used to
identify this study cohort. The University of Michigan
Institutional Review Board reviewed this proposal and
because it involved research using publically available data
sets, the Institutional Review Board felt approval was not
required because the data cannot be tracked to human
subjects.
The study cohort consisted of the 2742 patients
diagnosed with anaplastic thyroid cancer between 1998
and 2008. Data was censored at death or a minimum of 2
years after diagnosis (December 2010). Median follow-up
was 3.8 years. Prior to 2003, based on the fifth edition of
the American Joint Committee on Cancer (AJCC) Can-
cer Staging Manual, all anaplastic thyroid cancer patients
were classified as AJCC stage IV. After 2003, the sixth edi-
tion of the AJCC Cancer Staging Manual added the fol-
lowing subgroups to the anaplastic thyroid cancer cohort:
IVA, IVB, IVC.11 Per the sixth edition of the AJCC Can-
cer Staging Manual, anaplastic thyroid cancers with intra-
thyroidal, surgically resectable tumors with or without
lymph node involvement and without distant metastases
are stage IVA. If the primary tumor is extrathyroidal and
unresectable, with or without lymph node involvement
and without distant metastases, the cancer is stage IVB.
Any distant metastasis leads to categorization as stage
IVC.11 Given the change in staging categories, a separate
subgroup analysis was performed using the more contem-
porary cohort (2003-2008) with AJCC stage categories
IVA, IVB, and IVC.
Measures
Because anaplastic thyroid cancer is thought to develop af-
ter well-differentiated thyroid cancer,3 we divided age
into categories that are known to have survival implica-
tions for well-differentiated thyroid cancer: 44, 45-64,
and 65 years. Due to the large number of patients 65
years, we subsequently divided this cohort into patients
aged 65-74, 75-84, and 85 years. Because there were a
small number of races other than black or white, the
Asian, American Indian/Alaska Native, and Native Ha-
waiian and Pacific Islander categories were collapsed into
an “other” race category. Ethnicity was divided into non-
Hispanic and Hispanic. Persons of Hispanic origin could
be any race and therefore race instead of ethnicity was
included in the multivariable analysis. Insurance status
was categorized as the following: Private/government,
Medicare, Medicaid, Uninsured, or Unknown. By match-
ing the ZIP code of the patient recorded at the time of
diagnosis against files derived from year 2000 US Census
data, income and education level less than a high school
diploma were assigned to each patient. By matching the
patient’s state and county Federal Information Processing
Standard code recorded at the time of diagnosis against
files published by the US Department of Agriculture Eco-
nomic Research Service, the rural-urban continuum vari-
able was created. Treatment information included surgery
(total thyroidectomy, lobectomy) or no surgery, use of
radiation, and use of chemotherapy.
Statistical Analysis
Our outcome of interest was overall survival. Univariate
analysis was performed using the Kaplan-Meier method
with log-rank statistic to detect differences in overall
survival.
Cox proportional hazard regression modeling was
used for multivariable analysis. If the 95% confidence
interval (CI) of the hazards ratio did not cross 1.00, then
the relationship was considered statistically significant.
RESULTS
As shown in Table 1, the majority of patients with ana-
plastic thyroid cancer were women (61.9%) and 65 years
or older (69.5%). The mean age of our sample was
706 12.29 years. Eighty-six percent were white, 8.4%
were black, and only 4.0% fell into the “other” race cate-
gory. A small minority (6.0%) were Hispanic. Consistent
with the older age of the cohort, 58.1% of patients had
Medicare insurance. With respect to treatment, surgery
was omitted in 47.8% of the patients, radiation therapy
was omitted in 39.0%, and chemotherapy was omitted in
59.2%.
Kaplan-Meier curves (Fig. 1) illustrate survival in
patients diagnosed between 1998 to 2008 based on treat-
ment with surgery, radiation, and chemotherapy. The me-
dian survival with total thyroidectomy was 6.2 months
versus 2.3 months without any surgery. Similarly, treat-
ment with radiation was associated with an almost 5-
month median survival versus close to 1.8 months with-
out therapy. Chemotherapy improved median survival
from 2.3 months to 5.9 months.
On univariate analysis, younger age, which was
age 44 (P< .001), private insurance (P< .001), lower
education (P5 .021), and treatment with surgery
(P< .001), radiation (P< .001), and chemotherapy
(P< .001) were associated with improved survival. As
demonstrated in Table 2, as age increased, the likelihood
of death increased. In the adjusted model, only older age
(adjusted hazard ratio [AHR] for age 85 was 3.43, 95%
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CI5 2.34-5.03) and omission of treatment were associ-
ated with greater mortality (omission of surgery:
AHR5 1.79, 95% CI5 1.61-1.99; omission of radia-
tion therapy: AHR5 1.56, 95% CI5 1.41-1.73; and
omission of chemotherapy: AHR5 1.79, 95%
CI5 1.61-1.99). We had data on comorbidity from 2003
to 2008. When we re-ran the Cox proportional hazard
regression with this smaller cohort and included comor-
bidity, having 1 comorbidity was associated with
AHR5 1.31 (95% CI5 1.13-1.51) and having 2 or
more comorbidities was associated with AHR5 1.63
(95% CI5 1.26-2.10). The addition of comorbidity did
not change the relationship between the other patient and
treatment variables and overall survival.
Figure 2 shows the Kaplan-Meier curves for the
more contemporary cohort (2003-2008) with N5 699.
Median survival of stage IVA anaplastic thyroid cancer
was 9.0 months versus 4.8 months for IVB and 3.0
months for IVC.
In Table 3, we evaluated combination therapy in
244 patients with stage IVA anaplastic thyroid cancer,
242 patients with stage IVB anaplastic thyroid cancer, and
163 patients with stage IVC anaplastic thyroid cancer.
The longest median survival in patients with stage IVA
was 11.2 months in patients who received surgery, radia-
tion, and chemotherapy (P< .001). Surgery and radia-
tion, without chemotherapy, was associated with a
median survival of 9.3 months. Patients with stage
IVB had median survival of 9.9 months when they
received surgery with radiation and chemotherapy and
median survival of 5.9 months when they just received
surgery and radiation (P< .001). Patients with stage IVC
had a 4.9-month median survival if they received surgery,
radiation, and chemotherapy and a 3.5-month median
survival if they only received surgery and radiation
(P< .001). Only 10 patients with stage IVC anaplastic
thyroid cancer received surgery and chemotherapy
(without radiation), but their median survival was 8.2
months.
DISCUSSION
In this large sample of patients treated across the United
States, younger age and more intensive treatment were
associated with improved survival in patients with ana-
plastic thyroid cancer. Within the subgroups of patients
with stages IVA, IVB, and IVC cancer, more intensive
treatment, specifically combination therapy, was associ-
ated with a statistically significant improvement in sur-
vival. However, the difference in median survival was
consistently 9 months or less with the survival difference
in the highest risk patients often differing by only a few
months. This improved survival may be related to treat-
ment selection bias, whereby the healthier patients with
less aggressive tumor biology are more likely to receive
treatment.
TABLE 1. Characteristics of Patients Diagnosed
With Anaplastic Thyroid Cancer Between 1998-
2008 (N52742)
Characteristic N (%)
Patient Characteristics
Sex
Male 1046 (38.1%)
Female 1696 (61.9%)
Age, years
44 81 (3.0%)
45-64 754 (27.5%)
65-74 753 (27.5%)
75-84 834 (30.4%)
85 320 (11.7%)
Race
White 2364 (86.2%)
Black 229 (8.4%)
Other 109 (4.0%)
Unknown 40 (1.5%)
Hispanic
Yes 164 (6.0%)
No 2352 (85.8%)
Unknown 226 (8.2%)
Insurance
Private/government 829 (30.2%)
Medicare 1592 (58.1%)
Medicaid 106 (3.9%)
Uninsured 87 (3.2%)
Unknown 128 (4.7%)
Income
<$30,000 389 (14.2%)
$30,000-35,000 497 (18.1%)
$35,000-45,900 779 (28.4%)
$46,0001 962 (35.1%)
Unknown 115 (4.2%)
Education level less than high school diploma
29% 476 (17.4%)
20%-28.9% 627 (22.9%)
14%-19.9% 632 (23.0%)
<14% 892 (32.5%)
Unknown 115 (4.2%)
Rural-urban continuum
Metropolitan population 2076 (75.7%)
Other 527 (19.2%)
Unknown 139 (5.1%)
Treatment
Surgery
Total thyroidectomy 896 (32.7%)
Lobectomy 481 (17.5%)
No surgery 1310 (47.8%)
Unknown 55 (2.0%)
Radiation
Yes 1596 (58.2%)
No 1070 (39.0%)
Unknown 76 (2.8%)
Chemotherapy
Yes 1063 (38.8%)
No 1623 (59.2%)
Unknown 56 (2.0%)
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Previous studies of anaplastic thyroid cancer have
been limited by the small number of patients included in
analyses.3,5,6,12 The results of these prior studies have
been conflicting, with some finding no survival benefit to
intensive treatment4 and others finding survival benefit
with surgery plus radiation,2,12,13 or a combination of sur-
gery, radiation, and chemotherapy.5,6
Interestingly, in our entire cohort, the hazard ratios
for the subgroups of age> 44 years were greater than the
hazard ratio for any individual treatment: surgery, radia-
tion therapy, or chemotherapy. When we controlled for
comorbidity in the contemporary cohort, the relationship
between age and prognosis persisted. This emphasizes the
relative importance of age at diagnosis in survival.
Although significantly associated with survival in multi-
variable analysis, extent of surgery, use of radiation ther-
apy, and use of chemotherapy were associated with a small
absolute difference in survival (median survival closer to 6
months instead of near 2 months).
When we restricted the analyses to patients with
AJCC stage IVA, IVB, and IVC cancer and looked at
combination therapy, we found that combination ther-
apy, typically comprising surgery, radiation, and chemo-
therapy, was associated with the longest median survival.
The largest difference in median survival (9.3 months)
was between the no-treatment versus multimodality treat-
ment in the patients with stage IVA anaplastic thyroid
cancer.
The survival benefit of these treatments should
be taken in context of the risks. Weekly doxorubicin
(10 mg/m2) with radiation is the most commonly
employed chemoradiotherapy regimen in the treatment
of anaplastic thyroid cancer.14 However, no random-
ized controlled trials are available to prove benefit for
concurrent chemoradiotherapy over radiation alone.
Justification for treatment is warranted, nonetheless, in
an effort to save patients from the devastating compli-
cations of suffocation. The potential benefits, however,
Figure 1. Kaplan-Meier curves show (A) overall survival of patients with anaplastic thyroid cancer undergoing total thyroidectomy
versus lobectomy versus no thyroid surgery, and overall survival of patients with anaplastic thyroid cancer on the basis of receipt
of (B) radiation and (C) chemotherapy.
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must be weighed against the toxicities from chemora-
diation. Skin changes, pharyngoesophagitis and trache-
itis have commonly been reported.15 Toxicity can be
lessened to a point when hyperfractionated radiother-
apy is administered.14,16 Daily radiation doses, exceed-
ing 3 Gy, increase the risk for myelopathy. Hence,
each patient’s treatment plan must be tailored accord-
ing to his or her performance status and other under-
lying comorbidities. Finally, malnutrition and weight
loss are also of concern in patients with anaplastic
thyroid cancer. In one institutional experience, 76%
of treated patients experienced a median weight loss
of 5% (range, 0%-20%) of initial body weight at the
onset of chemoradiotherapy. Percutaneous endoscopic
gastrostomy tubes were placed and were required over
the long term in almost 30% of patients.17
A limitation of this current study is that it is a de-
scriptive study and, unlike randomized controlled trials,
does not allow for stratification according to factors that
are associated with outcome. Although we did control for
all known patient characteristics, it is still probable that
the ability to resect the cancer correlates with both the
likelihood of surgery and the likelihood of improved sur-
vival, thus leading to treatment selection bias. Related to
treatment selection bias with resectability, it is also highly
likely that patients who are more fit receive more intensive
treatment and that their longer survival is related to their
health status rather than or in addition to the treatment
modalities received. Additional limitations of this study
are that intent of therapy, ie, curative versus palliative, are
not clearly defined when using data from a large national
registry and that income and education level can only be
TABLE 2. Cox Proportional Hazard Regression for Association of Patient Characteristics and Treatment
With Overall Survival
Characteristic N (%)
Median Survival,
mo (95% CI)
Unadjusted Hazard
Ratio (95% CI)
Adjusted Hazard
Ratio (95% CI)
Patient characteristics
Sex
Male 766 (36.7%) 3.8 (3.4, 4.1) 0.95 (0.87, 1.05) 1.07 (0.97, 1.17)
Female 1319 (63.3%) 3.2 (2.9, 3.5) - -
Age, y
44 56 (2.7%) 11.5 (8.8, 32.0) - -
45-64 571 (27.4%) 4.8 (4.0, 5.5) 2.25 (1.59, 3.17) 2.08 (1.47, 2.95)
65-74 567 (27.2%) 4.0 (3.5, 4.6) 2.48 (1.76, 3.50) 2.20 (1.53, 3.15)
75-84 637 (30.6%) 2.8 (2.4, 3.1) 3.44 (2.45, 4.84) 2.85 (1.97, 4.11)
85 354 (12.2%) 1.6 (1.2, 2.0) 4.85 (3.40, 6.92) 3.43 (2.34, 5.03)
Race
White 1825 (87.5%) 3.5 (3.2, 3.7) - -
Black 175 (8.4%) 3.3 (2.0, 4.6) 1.08 (0.92, 1.27) 1.14 (0.96, 1.36)
Other 85 (4.1%) 2.8 (2.3, 4.1) 1.23 (0.98, 1.54) 1.16 (0.92, 1.46)
Insurance
Private/government 664 (31.8%) 5.0 (4.4, 5.6) - -
Medicare 1274 (61.1%) 2.9 (2.7, 3.1) 1.41 (1.27, 1.55) 1.02 (0.89, 1.17)
Medicaid 81 (3.9%) 4.5 (2.2, 5.7) 0.99 (0.77, 1.28) 0.95 (0.73, 1.23)
Uninsured 66 (3.2%) 2.0 (1.4, 4.4) 1.30 (0.99, 1.71) 1.00 (0.76, 1.32)
Education level less than high school diploma
29% 381 (18.3%) 2.9 (2.5, 3.6) 1.20 (1.05, 1.36) 1.10 (0.96, 1.26)
20%-28.9% 493 (23.6%) 3.2 (2.8, 3.7) 1.11 (0.99, 1.26) 1.13 (1.00, 1.28)
14%-19.9% 499 (23.9%) 3.0 (2.7, 3.6) 1.16 (1.03, 1.31) 1.14 (1.01, 1.29)
<14% 712 (34.1%) 4.1 (3.7, 4.7) - -
Rural-urban continuum
Metropolitan population 1697 (81.4%) 3.5 (3.2, 3.8) 0.89 (0.80, 1.00) 0.92 (0.81, 1.03)
Other 388 (18.6%) 3.1 (2.8, 3.6) - -
Treatment
Surgery
Total thyroidectomy 686 (32.9%) 5.8 (5.1, 6.3) - -
Lobectomy 386 (18.5%) 4.5 (3.6, 5.2) 1.12 (0.98, 1.28) 1.01 (0.88, 1.15)
No surgery 1013 (48.6%) 2.3 (2.1, 2.5) 1.85 (1.67, 2.05) 1.79 (1.61, 1.99)
Radiation
Yes 1259 (60.4%) 4.9 (4.6, 5.4) - -
No 826 (39.6%) 1.7 (1.5, 1.9) 1.77 (1.61, 1.94) 1.56 (1.41, 1.73)
Chemotherapy
Yes 834 (40.0%) 6.0 (5.3, 6.4) - -
No 1251 (60.0%) 2.2 (2.0, 2.4) 1.65 (1.50, 1.81) 1.28 (1.15, 1.43)
Abbreviation: CI, confidence interval.
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categorized by ZIP code/census data. However, previous
work has found that use of census-based socioeconomic
status is valid.18
By evaluating this large cohort of patients with ana-
plastic thyroid cancer, we demonstrated a statistically sig-
nificant improvement in survival with more intensive
therapy. However, overall survival of all patients with ana-
plastic thyroid cancer is dismal, and more intensive
therapy leads to only small differences in median survival.
This study has implications for patients and providers.
The results call attention to the need for shared decision-
making with informed patient participants. The risks and
morbidity associated with each treatment (surgery, radia-
tion, and chemotherapy) and the marginal expected
improvement in survival should be explained to the
patient.19 Some patients and providers may decide that a
2-month prolongation of life approaches futility.20 The
aggressiveness of cancer care near the end of life has
increased in recent years,21 and yet a previous study evalu-
ating other advanced cancers found that many patients
receiving chemotherapy for incurable cancers do not under-
stand that the chemotherapy is unlikely to be curative.22 It
is not known whether patients with anaplastic thyroid can-
cer understand that in most patients with the disease, the
likelihood of cure with any treatment modality is low. For
some patients, the chance of an improved median survival
by 1 to 9 months may be worth any risk; for other patients,
this marginal treatment benefit may not be worth
Figure 2. Overall survival is shown for patients with anaplastic thyroid cancer who had American Joint Committee on Cancer
stage IVA, IVB, and IVC cancer.
TABLE 3. Stage-Stratified Survival Analysis of
Anaplastic Thyroid Cancer by Treatment for
Patients Diagnosed Between 2003 and 2008
Stage N (%)
Median Survival,
mo (95%
Confidence Interval)
Stage IVA
No treatment 8 (3.3%) 1.9 (0.3, 9.1)
Surgery only 70 (28.7%) 4.3 (3.1, 7.4)
Surgery1 radiation 55 (22.5%) 9.3 (5.9, 17.5)
Surgery1 chemotherapy 7 (2.9%) 6.4 (1.9, 37.3)
Surgery1 radiation1 chemotherapy 96 (39.3%) 11.2 (8.3, 15.0)
Stage IVB
No treatment 19 (7.9%) 0.9 (0.5, 2.4)
Surgery only 72 (29.8%) 2.1 (1.3, 2.5)
Surgery1 radiation 39 (16.1%) 5.9 (3.7, 8.1)
Surgery1 chemotherapy 10 (4.1%) 5.7 (1.5, 12.0)
Surgery1 radiation1 chemotherapy 79 (32.6%) 9.9 (6.4, 12.9)
Stage IVC
No treatment 18 (11.0%) 0.8 (0.4, 1.3)
Surgery only 41 (25.2%) 1.8 (1.3, 2.4)
Surgery1 radiation 17 (10.4%) 3.5 (1.6, 8.6)
Surgery1 chemotherapy 10 (6.1%) 8.2 (1.8, 18.9)
Surgery1 radiation1 chemotherapy 41 (25.2%) 4.9 (3.4, 6.3)
The table illustrates the survival benefit of the addition of surgery followed
by adjuvant therapy with radiation and chemotherapy. Due to small num-
bers, radiation only, chemotherapy only, and radiation plus chemotherapy
are not included in the table.
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the risks.23 The poor overall survival of all patients with
anaplastic thyroid cancer, regardless of treatment, empha-
sizes the need for informed patients whose preferences are
incorporated into treatment decision-making.
FUNDING SOURCES
This research was supported by National Institutes of Health award
1-K07-CA-154595-02.
CONFLICT OF INTEREST DISCLOSURE
F. Worden has provided expert testimony and has acted as a
member of the Speakers Bureau for and received travel support
from Bristol-Myers Squibb.
REFERENCES
1. National Cancer Institute. Surveillance, Epidemiology and End
Results (SEER) Program. www.seer.cancer.gov. Accessed November
1, 2011.
2. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A.
Anaplastic thyroid carcinoma. Treatment outcome and prognostic
factors. Cancer. 2005;103:1330-1335.
3. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H,
Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopatho-
logic study of 121 cases. Cancer. 1990;66:321-330.
4. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carci-
noma: a 50-year experience at a single institution. Surgery. 2001;
130:1028-1034.
5. Haigh PI, Ituarte PH, Wu HS, et al. Completely resected anaplastic
thyroid carcinoma combined with adjuvant chemotherapy and
irradiation is associated with prolonged survival. Cancer. 2001;91:
2335-2342.
6. Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in
locoregionally confined anaplastic thyroid carcinoma: a single-institu-
tion experience using aggressive multimodal therapy. Thyroid. 2011;
21:25-30.
7. Kim TY, Kim KW, Jung TS, et al. Prognostic factors for Korean
patients with anaplastic thyroid carcinoma. Head Neck. 2007;29:
765-772.
8. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors
for thyroid carcinoma. A population-based study of 15,698 cases
from the Surveillance, Epidemiology and End Results (SEER)
program 1973-1991. Cancer. 1997;79:564-573.
9. Smallridge RC, Ain KB, Asa SL, et al. American thyroid association
guidelines for management of patients with anaplastic thyroid can-
cer. Thyroid. 2012;22:1104-1139.
10. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National
Cancer Data Base: a powerful initiative to improve cancer care in
the United States. Ann Surg Oncol. 2008;15:683-690.
11. American Joint Committee on Cancer. Comparison guide: cancer
staging manual, fifth versus sixth edition. www.cancerstaging.org/
products/ajccguide.pdf. Accessed November 1, 2012.
12. Akaishi J, Sugino K, Kitagawa W, et al. Prognostic factors and treat-
ment outcomes of 100 cases of anaplastic thyroid carcinoma. Thy-
roid. 2011;21:1183-1189.
13. Chen J, Tward JD, Shrieve DC, Hitchcock YJ. Surgery and radio-
therapy improves survival in patients with anaplastic thyroid carci-
noma: analysis of the surveillance, epidemiology, and end results
1983-2002. Am J Clin Oncol. 2008;31:460-464.
14. Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid
carcinoma: three protocols combining doxorubicin, hyperfractionated
radiotherapy and surgery. Br J Cancer. 2002;86:1848-1853.
15. Kim JH, Leeper RD. Treatment of anaplastic giant and spindle cell
carcinoma of the thyroid gland with combination Adriamycin and
radiation therapy. A new approach. Cancer. 1983;52:954-957.
16. Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin
S. Combined doxorubicin, hyperfractionated radiotherapy, and sur-
gery in anaplastic thyroid carcinoma. Report on two protocols. The
Swedish Anaplastic Thyroid Cancer Group. Cancer. 1994;74:
1348-1354.
17. Sherman EJ, Lim SH, Ho AL, et al. Concurrent doxorubicin and radio-
therapy for anaplastic thyroid cancer: a critical re-evaluation including
uniform pathologic review. Radiother Oncol. 2011;101:425-430.
18. Krieger N. Overcoming the absence of socioeconomic data in medi-
cal records: validation and application of a census-based methodol-
ogy. Am J Public Health. 1992;82:703-710.
19. Smith TJ, Hillner BE. Explaining marginal benefits to patients,
when “marginal” means additional but not necessarily small. Clin
Cancer Res. 2010;16:5981-5986.
20. Kadakia KC, Moynihan TJ, Smith TJ, Loprinzi CL. Palliative com-
munications: addressing chemotherapy in patients with advanced
cancer. Ann Oncol. 2012;23(suppl 3): 29-32.
21. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks
JC. Trends in the aggressiveness of cancer care near the end of life.
J Clin Oncol. 2004;22:315-321.
22. Weeks JC, Catalano PJ, Cronin A, et al. Patients’ expectations about
effects of chemotherapy for advanced cancer. N Engl J Med. 2012;
367:1616-1625.
23. Wright AA, Mack JW, Kritek PA, et al. Influence of patients’ prefer-
ences and treatment site on cancer patients’ end-of-life care. Cancer.
2010;116:4656-4663.
Treatment of Anaplastic Thyroid Cancer/Haymart et al
Cancer September 1, 2013 3139
